Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05153772 | Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients | PHASE2 | ACTIVE NOT_RECRUITING | 69 | — | — | Dec 21, 2021 | Dec 1, 2030 | Apr 15, 2026 | 4 | United States |
The morphological imaging (CT/MRI) will be done before therapy and selected time points before therapy cycle to determine changes in the size of target lesions.
To assess the safety and tolerability of 212Pb-DOTAMTATE
| Arm | Type | Description |
|---|---|---|
| Pb212-DOTAMTATE | EXPERIMENTAL | investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors in PRRT naive patients (Cohort 1) and previous PRRT patients (Cohort 2) |
| Name | Type | Description |
|---|---|---|
| AlphaMedix | DRUG | 212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors |
Inclusion Criteria: * Male or female ≥18 years old with unresectable or metastatic histologically confirmed NET * Subjects must have received and progressed following somatostatin analog administration * For PRRT naive subjects, documented progression of disease following previous therapy within 12...